Abstract
In the recent years, there has been a growing interest in the use of novel approaches for the treatment of parasitic diseases such as schistosomiasis. Among the different approaches used, organometallic compounds were found to offer unique opportunities in the design of antiparasitic drug candidates. A ferrocenyl derivative, namely ferroquine, has even entered clinical trials as a novel antimalarial. In this short review, we report on the studies describing the use of organometallic compounds against schistosomiasis.
Financial & competing interests disclosure
This work was financially supported by the Swiss National Science Foundation (SNSF Professorships PP00P2_133568 and and PP00P2_157545 to GG), the European Research Council (ERC-2013-CoG 614739-A_HERO to JK), the University of Zurich (GG) and the Stiftung für Wissenschaftliche Forschung of the University of Zurich (GG). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.